Myeloperoxidase (MPO) is found in the azurophilic granules of normal myelocytic cells. Cytochemical staining for MPO activity is used clinically to distinguish myeloid from acute lymphoid leukemias (ALL). However, using a highly sensitive RT-PCR technique, it is possible to detect MPO mRNA in otherwise clear ALL. The significance of this finding remains poorly understood. We have extended our observations to a series of 57 patients with the primary diagnosis of ALL (46 patients tested at diagnosis and 11 cases at relapse). We identified 25 cases (43.8%) of MPO mRNA(+)/enzyme(−) ALL (17 B cell and eight T cell lineage). Expression of myeloid antigens (CD13 or CD33) were detected in nine of them, and remarkably, 18 cases (72%) displayed CD34. Of these 25 MPO mRNA(+) leukemias, 10 (40%) are Bcr-Abl positive (with P210 fusion transcript in five patients while the five remaining cases carried P190 transcript). Moreover, 11 of 16 myeloid negative cases were also negative for any type of Bcr-Abl and MLL rearrangement, indicating that MPO mRNA positivity is not either invariably related to that chromosomal abnormality or necessarily associated with the presence of other myeloid differentiation features. Interestingly, six of these 11 cases are T-ALL, suggesting the presence of some overlapping phase for T and myeloid lineage commitment. Taken together, these findings could suggest a separate biological disease with immature origin and bipotential differentiation capability, which involves B and T-ALL subtypes and should lead to new investigations regarding their prognostic impact.
Introduction
The French-American-British (FAB) classification of acute leukemias is based on the light microscopic detection of myeloperoxidase (MPO) activity in blast cells. Leukemias with MPO activity in Ͼ3% of blasts are classified as acute myeloid leukemia (AML) and usually express myeloid cell surface antigens. 1 Acute lymphoblastic leukemia (ALL) is an immunophenotypical and genotypical heterogeneous group of diseases. Leukemic cells from the majority of patients with ALL express on their surface a variety of protein antigens that are found at discrete stages of maturation on normal B or T lymphocyte precursors. 2, 3 Thus, leukemic clones from ALL patients are thought to originate from normal lymphoid progenitor cells arrested in the early stages of B or T lymphocyte ontogeny. 4, 5 It is now clear that a subset of ALL patients with morphology, cytochemistry and immunophenotype of lymphoid lineage can also express one or more myeloid antigens (My+ ALL).
stages of normal myeloid maturation, or the levels of MPO mRNA in acute leukemia, it has been demonstrated that significant levels of the MPO enzyme parallel myeloid maturation, being the most abundant protein of the mature granulocyte. 10 This enzyme may be absent or in undetectable low levels in early myeloid precursors, such as leukemic myeloblasts, whereas levels of MPO mRNA decrease or even disappear with maturation and become undetectable from the myelocyte stage. 11, 12 This makes MPO mRNA a good marker for identifying early myeloid precursors that may be cytochemically negative for enzyme. For instance, blast cells from some patients with acute poorly differentiated leukemia may transcribe the MPO gene in the absence of mRNA translation to protein. 13 In this way, we and others, have indicated in recent studies that low levels of MPO expression, sometimes detectable only at the RNA level, may also be seen in certain acute biphenotypic leukemias, cell lines of lymphoid lineage or even in B or T acute lymphoblastic leukemias. [14] [15] [16] [17] [18] [19] Furthermore, the true incidence and significance of this finding remain poorly understood with several issues largely unknown, such as the correlation with myeloid antigen expression, genetic markers, clinical data and thus the potential influence in clinical outcome.
We carried out this study in order to detect the MPO mRNA(+)/enzyme(−) phenotype in ALL. For this purpose, we examined blast cells of 57 patients with ALL diagnosed by morphologic, cytochemical, immunologic and molecular criteria, using a highly sensitive reverse transcription polymerase chain reaction (RT-PCR) detection method. The correlation of MPO mRNA expression with immunophenotype and genotype were also analyzed, together with the presenting clinical data, to find out whether this finding could be related to other known features, or could reflect a novel entity among ALLs.
Patients and methods
Between January 1993 and April 1998, 57 cases of ALL (46 B lineage and 11 T lineage) were included in this study. They fulfilled immunophenotypic and morphologic criteria for ALL, 46 cases were tested at diagnosis and 11 at relapse, both when peripheral blood samples were available. Chemotherapy was based on risk-adjusted treatment protocols of the BFM group. Thirty-three were male and 24 female, with ages ranging between 18 months and 72 years (median 13 years).
Diagnostic criteria
Bone marrow (BM) and peripheral blood (PB) specimens were stained by standard techniques, including May-GrunwaldGiemsa, periodic acid Schiff (PAS) reagent, myeloperoxidase, naphthol AS-D acetate esterase and acid phosphatase. The diagnosis of ALL was based on criteria established by the FAB classification and confirmed by immunologic and molecular criteria.
Immunophenotyping
Cell surface antigens were detected by direct immunofluorescence technique in flow cytometric analysis using a panel of monoclonal antibodies labeled with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) reactive with lymphoid and myeloid antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD22, CD13, CD14, CD33, CD34, HLA-Dr) (Becton Dickinson, San Jose, CA, USA). When myeloid antigens were expressed in at least 20% of cells, dual-fluorescence analysis was performed using PE-conjugated MnAbs against lymphoid antigens in order to confirm the coexpression of both antigens on the same cells. Data acquisition and analysis were performed using a Coulter Profile II (Hialeah, FL, USA). Analysis was restricted to the leukemic population by gating on forward and side light-scatter parameters.
For intracytoplasmic detection of MPO, CD22, CD3 and terminal desoxynucleotidyl transferase (Tdt), an immunocytochemical staining was performed using the alkaline phosphatase-antialkaline phosphatase technique and specific monoclonal antibodies MPO-7 (Dako, Glostrup, Denmark), CD22 and CD3 (Becton Dickinson) and Tdt (Immunotech, Marseille, France).
Molecular analysis
High-molecular weight DNA and total RNA were prepared from marrow cells at the time of diagnosis using conventional methods. 20, 21 Each DNA sample was digested with BamHI, HindIII, BglII and EcoRI. The probes used to detect immunoglobulin heavy-chain gene rearrangement (IgH) and T cell receptor ␤ rearrangement (TCR␤) were the commercially available JH DNA probe and CT␤ probe (Oncogene Science, New York, NY, USA). 11q23 abnormalities were studied with the B859 probe kindly provided by Dr G Cimino. 22 Bcr-210 and Bcr-190 Philadelphia translocation were detected using the reverse transcription-polymerase chain reaction (RT-PCR) according to Saglio et al. 23 
In vitro amplification of MPO transcript
Reverse transcription was performed on 1 g of total RNA from PB, after heating at 70°C for 5 min, with random hexamers as reaction primer. The reaction was carried out at 42°C for 45 min in the presence of 12 units of AMV reverse transcriptase (Boehringer, Mannheim, Germany). Five microliters of RT products were used for one round of PCR amplification of the MPO transcripts using the protocol previously described by Zhang et al. 24 The amplified products (20 l) were migrated in 1.5% agarose gel containing 1 g/ml ethidium bromide and photographed. A band of 537 bp was observed in patients who expressed MPO ( Figure 1 ).
For each preparation of RNA obtained from leukemic cells, a positive (peripheral cells from an AML-M1 patient) and a negative control (peripheral cells from healthy BMT donors) were included. Each sample was divided into at least two aliquots and extracted separately on two different occasions. A blank control that included all reagents except RNA was added at the cDNA stage to control for contamination with the PCR product. False positives for MPO were ruled out using total RNA isolated from PB (no metamyelocytes or more immature forms were seen in the differential counts). Precautions were taken in order to ensure high PCR quality as recommended by Kwok and Higuchi. 25 Amplification of RAR␣ gene transcript was performed to assess RNA integrity.
To evaluate the sensitivity of this assay, serial dilutions of AML-M1 cells with cells from a healthy donor were carried out, and RNA extracted from each mixture and assayed by RT-PCR. MPO mRNA was detected in a mixture of one leukemic cell per 10 
Statistical analysis
Differences in the distribution of clinical and biological features among subgroups of patients were analyzed by the twotailed Fisher's exact test for categorical data and the Wilcoxon test for continuous data.
Results

Molecular studies
Out of 57 ALL cases studied, 25 (43.8%) were MPO mRNA positive/enzyme negative (17 B lineage and eight T lineage). Leukemic cells from 36% of patients with myeloid antigen negative ALL and 69% of patients with ALL coexpressing myeloid antigens were MPO mRNA(+)/enzyme(−) (Table 1A) . Additionally, of 57 analyzed samples, 12 (21%) were found to be Bcr-Abl positive. Six patients showed findings consistent with the P190 subtype, another three patients the P210 subtype and three cases showed both transcript subtypes. Moreover, 33% of patients with Bcr-Abl negative ALL and 83% of patients with ALL expressing Bcr-Abl rearrangement were MPO mRNA(+). Only two Bcr-Abl(+)/ALL patients showed MPO mRNA(−) and the remaining were Bcr-Abl(+)/MPO mRNA(+) ( Table 1B ). In addition, 18% of patients without BcrAbl and 42% of cases with Bcr-Abl-positive ALL expressed myeloid antigens (Table 1C) .
The results of molecular analysis in MPO mRNA(+)/ALL are summarized in Tables 2 and 3 (tested at diagnosis and relapse, respectively). All cases lacked MLL gene (11q23) rearrange- 
a Died. CR, complete remission; RLP, relapse; EFS, event-free survival. 
Immunophenotype
The immunophenotypic analysis performed in all 57 ALL patients confirmed 46 B cell lineage and 11 T cell lineage leukemias. In addition, 13/57 patients (23%) expressed both lymphoid and myeloid surface antigens on leukemic cells. All patients were intracytoplasmic MPO enzyme negative.
In Tables 2 and 3 , immunophenotyping results in ALL/MPO(+) are reported. The expression of T cell markers was demonstrated in eight patients, B cell markers in 17 and none showed coexpression of both T and B cell markers. CD13 or CD33 antigens were expressed in nine cases (36%), but no cases of T-ALL showed myeloid antigens. Additional immunological studies revealed that CD34 antigen was present in 72% of MPO mRNA(+) patients and in 90% of BcrAbl-positive patients.
Morphological and clinical findings
Clinical data such as age, sex, hemoglobin, white blood cell (WBC) count, platelets, FAB morphologic classification and high-risk subgroup of MPO mRNA(+)/ALL patients were compared with MPO mRNA(−)/ALL cases (Table 4) . Both groups of patients have similar presenting features. The different features in MPO(+)/ALL patients were limited to the increased presence of males in this group. However, there are significant differences in Bcr-Abl positivity between the groups (10/25 vs 2/32, P = 0.0019), myeloid antigens expression (9/25 vs 4/32, P = 0.0358) and T lineage (8/25 vs 3/32, P = 0.0446), with increased percentages in the MPO-positive group.
The incidence of MPO mRNA positivity found in patients studied at relapse was slightly higher than that found in group of patients tested at diagnosis, although there was not a statistical difference (54.5% vs 41.3%).
Discussion
In the present study, we extend our earlier analysis of MPO mRNA expression in acute leukemia cells lacking detectable MPO activity. Previously, we established that some cases of My(−)/MPO(−) enzyme ALL could express MPO mRNA by RT-PCR.
14 With this larger series, we found that leukemic cells from a significant percentage of patients (43.8%) with B or T lineage ALL (including those with either My(−) ALL or coexpressing myeloid antigen) also express the MPO gene in the absence of functional enzyme.
The incidence of MPO mRNA(+) ALL blasts, has been reported to be variable from 0 to 46% in My(−) cases, to 83% in ALL which coexpress myeloid surface markers. [15] [16] [17] [18] Our results agree with previous studies, but our RT-PCR assay is more sensitive than those studies carried out using Northern blot, which tends to underestimate the prevalence of this finding. To the best of our knowledge, this study represents the largest series of ALL patients analyzed for MPO gene expression together with other molecular and immunopheno- typic markers to correlate all these findings. In addition, since several authors employed BM samples to detect RNA expression, it is possible that in some cases the MPO positivity was due to residual normal myeloid cell population. Thus, we employed the technique reported by Zhang et al, 24 where the diagnosis of MPO mRNA(+) was established by RT-PCR using only PB, to guard against the possibility that even small numbers of normal myeloblasts and promyelocytes in the BM might give a false-positive result, when techniques with high sensitivity are used. The blasts found in the PB at the time of diagnosis can be presumed to be entirely of the leukemic clone. This is in agreement with similar MPO mRNA negativity of normal PB samples in the study by Crisan et al, 26 using a different RT-PCR procedure. Despite technical differences, our experience combined with those of others, provides convincing evidence of MPO mRNA positivity in typical ALL with lymphoid immunophenotype, genotype and morphology in the absence of translation to protein.
The expression of MPO gene and/or other myeloid markers by ALL cells is speculated as reflecting either lineage infidelity due to aberrant gene expression, neoplastic transformation of rare bilineage lymphoid/myeloid progenitor cells, or transformation of a multipotent lymphohematopoietic precursor cell. 27 These malignant phenotypes may result due to certain chromosomal abnormalities, such as Philadelphia (Ph) translocation or 11q23 abnormalities with Bcr-Abl and MLL gene rearrangement respectively, two well-known entities with bipotential lymphoid and myeloid differentiation capability. [28] [29] [30] The presence of MLL in our MPO mRNA(+) leukemic specimens was sought, but 100% negativity was found probably due to the absence of infants in our series. However, consistently with recent studies in childhood and adult Bcr-Abl-positive ALL, 31 the global incidence of Bcr-Abl cases in our series was 21%, and 83% of them were MPO mRNA(+), but only 10/25 MPO positive showed Bcr-Abl rearrangement. In this sense, Crisan et al 18 found that MPO mRNA(+)/ALL is associated with the positivity for the major-Bcr breakpoint of chronic myelogenous leukemia (CML), that yields a P210 fusion transcript. Thus, cases were considered as CML presenting in blast crisis of lymphoid lineage, as opposed to de novo ALL. Our results confirm this finding, but we have also shown the expression of MPO mRNA in de novo Bcr-Abl-positive ALL with minor-Bcr breakpoint. These data question the lymphoid lineage restrictions of de novo Ph-positive ALL, suggesting a multilineage involvement in the oncogenic process, and thus an origin at the level of early hemopoietic stem cells. In contrast with Anastasi et al, 32 who in a review of the literature regarding cell lineage-specific investigations, recently postulated that major-Bcr transcript involves all cell lineages whereas Ph-positive ALL with a minor-Bcr rearrangement is restricted only to the lymphoblastic cell compartment. It should be noted that the loss of myeloid differentiation capability appears to be incomplete since MPO gene expression is still detected at the mRNA level in most of our P190-positive ALL cases.
Furthermore, the presence of CD34, a 110 kDa integral membrane protein thought to be expressed normally by immature hematopoietic progenitor cells, was detected in most (72%) MPO mRNA(+) ALL cases in our experience. Similar findings were detected in Bcr-Abl(+) ALL, and it has also been reported in childhood Ph(+)/ALL and monosomy 7 33 as well as in adults with Ph-positive acute leukemia, 34 suggesting that the oncogenic event occurred in an early progenitor cell. 33 Although in this study, nine cases of MPO mRNA(+) leuke-mias expressed myeloid antigens such as CD13 or CD33, the remaining 16 cases did not. This demonstrates that the expression of MPO is not necessarily associated with the presence of other myeloid differentiation features. Moreover, 11 of these 16 myeloid-negative cases, were also negative for any type of Bcr-Abl rearrangement, indicating that MPO mRNA positivity is not invariably related to that chromosomal abnormality. Interestingly, six of these 11 cases were T-ALL, suggesting the presence of some overlapping phase for T and myeloid-lineage commitment during the immature stages of ontogeny. According to this finding, the expression or in vitro induction of myeloid antigens by T-ALL cells has already been reported. 35 Likewise, Yoneda et al 36 studying immature stage T-ALL found co-expression of the genes of MPO and CD3 and the expression of myeloid antigens related to the immaturity of these neoplastic T cells.
In conclusion, MPO mRNA(+) ALL seem to be a stem cell disease with bipotential differentiation capability, which involves B-and T-ALL subtypes, independently of Bcr-Abl and MLL rearrangement. These findings support the idea of a separate biologically determined subgroup in ALL patients and reinforce the need for further prospective studies with a long follow-up period and larger series, to determine the prognostic significance of these findings. In addition, because of the high sensitivity of this RT-PCR assay, it could also be useful in detecting minimal residual disease, in recognizing an early recurrence of leukemia and in monitoring response to chemotherapy performing consecutive PCR analysis.
